Translating mismatch repair mechanism into cancer care

Current Drug Targets

Volumn 15, Issue 1, 2014, Pages 53-64

  Heinen, Christopher D ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Alkylating agents; Chemoresistance; Cisplatin; Colorectal cancer; Lynch syndrome; Microsatellite instability; Mismatch repair

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 8 HYDROXYGUANINE; ACETYLSALICYLIC ACID; BELINOSTAT; BORTEZOMIB; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYTOSINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOMUSTINE; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PSORALEN; TEMOZOLOMIDE; BRCA1 PROTEIN; BRCA2 PROTEIN; DECITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN MSH3;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER THERAPY; DNA DAMAGE; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE MUTATION; HEALTH CARE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL DECISION MAKING; DNA BINDING; DNA CROSS LINKING; ESCHERICHIA COLI; PROTEIN EXPRESSION;

BASE PAIR MISMATCH; DNA REPAIR; HUMANS; NEOPLASMS;

EID: 84892992470     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450114666140106100128     Document Type: Review

References (165)

1. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027-38.
2. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215-25.
3. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature, 1994; 368: 258-61.
4. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263: 1625-9.
5. Kolodner RD, Tytell JD, Schmeits JL, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999; 59: 5068-74.
6. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75-80.
7. Worthley DL, Walsh MD, Barker M, et al. Familial mutations in PMS2 can cause autosomal dominant hereditary nonpolyposis colorectal cancer. Gastroenterology 2005; 128: 1431-6.
8. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition--Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 2004; 20: 269-76.
9. Lynch H, Lynch P, Lanspa S, Snyder C, Lynch J, Boland C. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clinical Genetics 2009; 76: 1-18.
10. Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012; 30: 4409-15.
11. Strand M, Prolla TA, Liskay RM, Petes TD. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair Nature 1993; 365: 274-6.
12. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-6.
13. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-61.
14. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-9.
15. Bocker T, Ruschoff J, Fishel R. Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects. Biochim Biophys Acta 1999; 1423: O1-O10.
16. Boland CR. Evolution of the Nomenclature for the Hereditary Colorectal Cancer Syndromes. Fam Cancer 2005; 4: 211-8.
17. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424-5.
18. Rodriguez-Bigas M, Boland C, Hamilton S, et al. A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst, 1997; 89: 1758-62.
19. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability. J Natl Cancer Inst 2004; 96: 261-8.
20. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-6.
21. Lynch HT, Lynch PM. Molecular Screening for the Lynch Syndrome--Better Than Family History? N Engl J Med 2005; 352: 1920-2.
22. Boland CR, Thibodeau SN, Hamilton SR, et al. A National cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
23. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors. J Clin Oncol 2002; 20: 1043-8.
24. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). N Engl J Med 2005; 352: 1851-60.
25. Byfield SAD, Syngal S. Clinical Guidelines Versus Universal Molecular Testing: Are We Ready to Choose an Optimal Strategy for Lynch Syndrome Identification. Am J Gastroenterol 2008; 103: 2837-40.
26. Julie C, Tresallet C, Brouquet A, et al. Identification in daily practice of patients with lynch syndrome (hereditary nonpolyposis colorectal cancer): revised bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 2008; 103: 2825-35.
27. Morrison J, Bronner M, Leach BH, Downs-Kelly E, Goldblum JR, Liu X. Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: From the revised Bethesda guidelines to a universal approach. Scand J Gastroenterology 2011; 46: 1340-8.
28. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 2012; 61: 865-72.
29. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997; 57: 4749-56.
30. Hartmann A, Zanardo L, Bocker-Edmonston T, et al. Frequent Microsatellite Instability in Sporadic Tumors of the Upper Urinary Tract. Cancer Res 2002; 62: 6796-802.
31. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993; 53: 5100-3.
32. Simpkins SB, Bocker T, Swisher EM, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet, 1999; 8: 661-6.
33. Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008; 29: 673-80.
34. Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159: 2107-16.
35. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet, 2008; Chapter 10: Unit 10 11.
36. Cunningham J, Christensen E, Tester D, Kim C, Roche P, Burgart L, Thibodeau S. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58: 3455-60.
37. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-5.
38. Kane M, Loda M, Gaida G, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808-811.
39. Thibodeau SN, French AJ, Roche PC, et al. Altered Expression of hMSH2 and hMLH1 in Tumors with Microsatellite Instability and Genetic Alterations in Mismatch Repair Genes. Cancer Res 1996; 56: 4836-40.
40. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93.
41. Toyota M, Issa J-PJ. CpG island methylator phenotypes in aging and cancer. Sem Can Biol 1999; 9: 349-57.
42. Issa J-P. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-993.
43. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012; 49: 151-7.
44. Bouzourene H, Hutter P, Losi L, Martin P, Benhattar J. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam Cancer 2010; 9: 167-72.
45. Jensen LH, Lindebjerg J, Byriel L, Kolvraa S, Crüger DG. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Colorectal Disease 2008; 10: 490-7.
46. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6: 301-10.
47. Samowitz WS, Curtin K, Ma K-N, et al. Microsatellite Instability in Sporadic Colon Cancer Is Associated with an Improved Prognosis at the Population Level. Can Epidemiol Biomark Prev 2001; 10: 917-23.
48. Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
49. Hsieh P, Yamane K. DNA mismatch repair: Molecular mechanism, cancer, and ageing. Mechanisms of Ageing Dev 2008; 129: 391-407.
50. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7: 335-46.
51. Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Gen Dev 1999; 9: 89-96.
52. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 1996; 65: 101-33.
53. Kunkel TA, Erie DA. DNA MISMATCH REPAIR. Ann Rev Biochemistry, 2005; 74: 681-710.
54. Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, Kolodner R, Fishel R. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 1996; 93: 13629-34.
55. Fishel R. Mismatch repair, molecular switches, and signal transduction. Genes Dev 1998; 12: 2096-101.
56. Dzantiev L, Constantin N, Genschel J, Iyer RR, Burgers PM, Modrich P. A defined human system that supports bidirectional mismatch-provoked excision. Mol Cell 2004; 15: 31-41.
57. Zhang Y, Yuan F, Presnell SR, et al. Reconstitution of 5'-Directed Human Mismatch Repair in a Purified System. Cell 2005; 122: 693-705.
58. Peltomaki P. Lynch Syndrome Genes. Fam Cancer 2005; 4: 227-32.
59. Wu Y, Berends MJ, Sijmons RH, et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001; 29: 137-8.
60. Edelmann W, Umar A, Yang K, et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res 2000; 60: 803-7.
61. Wu Y, Berends MJ, Post JG, et al. Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology 2001; 120: 1580-7.
62. Wei K, Clark AB, Wong E, et al. Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev 2003; 17: 603-14.
63. Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 1995; 5: 382-95.
64. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-8.
65. Duval A, Hamelin R. Mutations at Coding Repeat Sequences in Mismatch Repair-deficient Human Cancers: Toward a New Concept of Target Genes for Instability. Cancer Res 2002; 62: 2447-54.
66. Mori Y, Yin J, Rashid A, et al. Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Can Research 2001; 61: 6046-9.
67. Percesepe A, Kristo P, Aaltonen LA, Ponz de Leon M, de la Chapelle A, Peltomaki P. Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability. Oncogene 1998; 17: 157-63.
68. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
69. Cejka P, Stojic L, Mojas N, et al. Methylation-induced G2/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J 2003; 22: 2245-54.
70. Duarte S, Carle G, Faneca H, Lima MCPd, Pierrefite-Carle V. Suicide gene therapy in cancer: Where do we stand now? Can Letters 2012; 324: 160-70.
71. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-401.
72. Ernst RJ, Komor AC, Barton JK. Selective Cytotoxicity of Rhodium Metalloinsertors in Mismatch Repair-Deficient Cells. Biochemistry 2011; 50: 10919-28.
73. Hart JR, Glebov O, Ernst RJ, Kirsch IR, Barton JK. DNA mismatch-specific targeting and hypersensitivity of mismatchrepair-deficient cells to bulky rhodium(III) intercalators. Proc Natl Acad Sci USA 2006; 103: 15359-63.
74. Jackson BA, Alekseyev VY, Barton JK. A versatile mismatch recognition agent: specific cleavage of a plasmid DNA at a single base mispair. Biochemistry 1999; 38: 4655-62.
75. Fishel R. Signaling mismatch repair in cancer. Nat Med 1999; 5: 1239-41.
76. Heinen CD, Schmutte C, Fishel R. DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Can Biol Ther 2002; 1: 477-85.
77. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair 2004; 3: 1091-101.
78. Kaina B, Ziouta A, Ochs K, Coquerelle T. Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat Res 1997; 381: 227-41.
79. Mojas N, Lopes M, Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent singlestranded gaps in newly replicated DNA. Genes Dev 2007; 21: 3342-55.
80. Noonan EM, Shah D, Yaffe MB, Lauffenburger DA, Samson LD. O 6-Methylguanine DNA lesions induce an intra-S-phase arrest from which cells exit into apoptosis governed by early and late multi-pathway signaling network activation. Integrative Biology 2012; 4: 1237-55.
81. Adamson A, Beardsley D, Kim W, Gao Y, Baskaran R, Brown K. Methylator-induced, Mismatch Repair-dependent G2 Arrest Is Activated through Chk1 and Chk2. Mol Biol Cell 2005; 16: 1513-26.
82. Liu Y, Fang Y, Shao H, Lindsey-Boltz L, Sancar A, Modrich P. Interactions of Human Mismatch Repair Proteins MutS and MutL with Proteins of the ATR-Chk1 Pathway. J Biol Chem 2010; 285: 5974-82.
83. Wang Y, Qin J. MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci USA 2003; 100: 15387-92.
84. Yoshioka K, Yoshioka Y, Hsieh P. ATR Kinase Activation Mediated by MutSa and MutLa in Response to Cytotoxic O6-Methylguanine Adducts. Mol Cell 2006; 22: 501-10.
85. Hawn MT, Umar A, Carethers JM, et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Can Research 1995; 55: 3721-5.
86. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-11.
87. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage. J Biol Chem 2005; 280: 5516-26.
88. Carethers JM, Chauhan DP, Daniel F, et al. Mismatch repair proficiency and In vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123-31.
89. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. International J Cancer 2003; 106: 66-73.
90. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-90.
91. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
92. Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45-52.
93. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with mutlα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996; 271: 19645-8.
94. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. The Lancet 2000; 355: 1745-50.
95. Hemminki A, Mecklin J-P, Järvinen H, A. Aaltonen L, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921-8.
96. Liang J-T, Huang K-C, Lai H-S, et al. High-frequency microsatellite instability predicts better chemosensitivity to highdose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 2002; 101: 519-25.
97. Niv Y. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil. Isr Med Assoc J 2005; 7: 520-4.
98. Benatti P, Gafa R, Barana D, et al. Microsatellite Instability and Colorectal Cancer Prognosis. Clin Cancer Res 2005; 11: 8332-40.
99. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394-401.
100. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy on colorectal cancer. Gut 2006; 55: 848-55.
101. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med, 2003; 349: 247-57.
102. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-26.
103. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA Mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Nat Can Inst 2011; 103: 863-75.
104. Duckett D, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM, Modrich P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 1996; 93: 6443-7.
105. Mello JA, Acharya S, Fishel R, Essigmann JM. The mismatchrepair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 1996; 3: 579-89.
106. Watanabe Y, Koi M, Hemmi H, Hoshai H, Noda K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 2001; 85: 1064-9.
107. Mayer F, Gillis AJM, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LHJ. Microsatellite Instability of Germ Cell Tumors Is Associated with Resistance to Systemic Treatment. Can Research 2002; 62: 2758-60.
108. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10: 4420-26.
109. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000; 6: 1415-21.
110. Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 1998; 77: 741-6.
111. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007; 13: 2038-45.
112. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009; 15: 4622-9.
113. Maxwell JA, Johnson SP, McLendon RE, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008; 14: 4859-68.
114. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335-41.
115. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor Xenografts by 2'-Deoxy-5-azacytidine-induced Demethylation of the hMLH1 Gene Promoter. Cancer Res 2000; 60: 6039-44.
116. Steele N, Finn P, Brown R, Plumb JA. Combined inhibition of DNA methylation and histone acetylation enhances gene reexpression and drug sensitivity In vivo. Br J Cancer 2009; 100: 758-63.
117. Matei D, Fang F, Shen C, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72: 2197-205.
118. Tawbi HA, Beumer JH, Tarhini AA, et al. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncology 2013; 24: 1112-9.
119. Mastrocola AS, Heinen CD. Lynch syndrome-associated mutations in MSH2 alter DNA repair and checkpoint response functions In vivo. Human Mutation 2010; 31: E1699-708.
120. Heinen CD. Genotype to phenotype: Analyzing the effects of inherited mutations in colorectal cancer families. Mutation Research/DNA Repair 2010; 693: 32-45.
121. Gammie AE, Erdeniz N, Beaver J, Devlin B, Nanji A, Rose MD. Functional characterization of pathogenic human MSH2 missense mutations in Saccharomyces cerevisiae. Genetics 2007; 177: 707-21.
122. Arlow T, Scott K, Wagenseller A, Gammie A. Proteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2. Proc Natl Acad Sci USA 2013; 110: 246-51.
123. DeWeese TL, Shipman JM, Larrier NA, et al. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc Natl Acad Sci USA 1998; 95: 11915-20.
124. Mazurek A, Berardini M, Fishel R. Activation of Human MutS Homologs by 8-Oxo-guanine DNA Damage. J Biol Chem 2002; 277: 8260-6.
125. Ni TT, Marsischky GT, Kolodner RD. MSH2 and MSH6 are required for removal of adenine misincorporated opposite 8-oxoguanine in S. cerevisiae. Mol Cell 1999; 4: 439-44.
126. Zlatanou A, Despras E, Braz-Petta T, et al. The hMsh2-hMsh6 complex acts in concert with monoubiquitinated PCNA and POL ETA in response to oxidative DNA damage in human cells. Mol Cell 2011; 43: 649-62.
127. Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Molecular Medicine 2009; 1: 323-37.
128. Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 2010; 16: 5107-13.
129. Morrison A, Johnson AL, Johnston LH, Sugino A. Pathway correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J 1993; 12: 1467-73.
130. Tran HT, Keen JD, Kricker M, Resnick MA, Gordenin DA. Hypermutability of homonucleotide runs in mismatch repair and DNA polymerase proofreading yeast mutants. Mol Cell Biol 1997; 17: 2859-65.
131. Argueso JL, Smith D, Yi J, Waase M, Sarin S, Alani E. Analysis of conditional mutations in the saccharomyces cerevisiae MLH1 Gene in mismatch repair and in meiotic crossing over. Genetics 2002; 160: 909-21.
132. Martin SA, McCabe N, Mullarkey M, et al. DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1. Cancer Cell 2010; 17: 235-48.
133. Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res 2011; 71: 1836-48.
134. Chang DK, Goel A, Ricciardiello L, et al. Effect of H2O2 on cell cycle and survival in DNA mismatch repair-deficient and-proficient cell lines. Cancer Letters 2003; 195: 243-51.
135. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
136. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
137. Woodhouse BC, Dianov GL. Poly ADP-ribose polymerase-1: An international molecule of mystery. DNA Repair 2008; 7: 1077-86.
138. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-82.
139. Horton TM, Jenkins G, Pati D, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Thera 2009; 8: 2232-42.
140. Vilar E, Bartnik CM, Stenzel SL, et al. MRE11 deficiency increases sensitivity to Poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011; 71: 2632-42.
141. Gaymes TJ, Mohamedali AM, Patterson M, et al. Microsatellite instability induced mutations in DNA repair genes Ctip and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors in myeloid malignancies. Haematologica 2013; 98: 1397-406.
142. Leichman L, Cohen S, Hochster H, et al. A phase II trial to assess the single-agent efficacy and safety of the PARP inhibitor olaparib in previously treated patients with metastatic, measurable colorectal cancer stratified by microsatellite status. Proceedings of the ASCONCI-EORTC Annual Meeting on Molecular Markers in Cancer 2010; 118.
143. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001; 61: 6555-62.
144. Hsiang Y-H, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
145. Fallik D, Borrini F, Boige V, et al. microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63: 5738-44.
146. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814-21.
147. Braun MS, Richman SD, Quirke P, et al. Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial. J Clin Oncol 2008; 26: 2690-8.
148. Kim JE, Hong YS, Ryu M-H, et al. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Sci 2011; 102: 1706-11.
149. Aquilina G, Ceccotti S, Martinelli S, Hampson R, Bignami M. N-(2-Chloroethyl)-Nα-cyclohexyl-N-nitrosourea Sensitivity in Mismatch Repair-defective Human Cells. Cancer Res 1998; 58: 135-41.
150. Fiumicino S, Martinelli S, Colussi C, et al. Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells In vitro and in xenografts. Int J Cancer 2000; 85: 590-6.
151. Wu Q, Christensen LA, Legerski RJ, Vasquez KM. Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep 2005; 6: 551-57.
152. Papouli E, Cejka P, Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 2004; 64: 3391-4.
153. Peng M, Litman R, Xie J, Sharma S, Brosh RM, Jr., Cantor SB. The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. EMBO J 2007; 26: 3238-49.
154. Xie J, Guillemette S, Peng M, Gilbert C, Buermeyer A, Cantor SB. An MLH1 Mutation Links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy. Cancer Prev Res 2010; 3: 1409-16.
155. de Jong A, Nagengast F, Kleibeuker J, et al. What is the appropriate screening protocol in Lynch syndrome? Fam Cancer 2006; 5: 373-8.
156. Celentano V, Luglio G, Antonelli G, Tarquini R, Bucci L. Prophylactic surgery in Lynch syndrome. Techn Coloproctol 2011; 15: 129-34.
157. Jarvinen H, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen L, Mecklin J. Ten Years After Mutation Testing for Lynch Syndrome: Cancer Incidence and Outcome in Mutation-Positive and Mutation-Negative Family Members. J Clin Oncol 2009; 27: 4793-7.
158. Schmeler KM, Lynch HT, Chen L-m, et al. Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome. N Engl J Med 2006; 354: 261-9.
159. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Int Med 1998; 129: 787-96.
160. Lynch HT. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis Colon Rectum 1996; 39: 109-10.
161. Church JM. Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann Med 1996; 28: 479-82.
162. Dubé C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U. S. preventive services task force. Ann Int Med 2007; 146: 365-75.
163. Burn J, Bishop D, Mecklin J, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359: 2567-78.
164. Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet 2011; 378: 2081-7.
165. Mcilhatton MA, Tyler J, Kerepesi LA, et al. Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prev Res 2011; 4: 684-93.